<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509990</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981CVE01</org_study_id>
    <nct_id>NCT00509990</nct_id>
  </id_info>
  <brief_title>Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting</brief_title>
  <official_title>Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      An open-label, multicenter study, of long term management to evaluate effectiveness,&#xD;
      tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate&#xD;
      atopic dermatitis in a daily practice&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effectiveness of pimecrolimus cream 1% in the long-term management in mild to moderate atopic dermatitis in pediatric patients in a daily practice, as assessed by: • Investigator Global Assessment • Facial Investigator Global Ass</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>• To monitor the safety of pimecrolimus cream 1% in the long-term management as assessed by Adverse Events and Serious Adverse Events collection • To evaluate quality of life of both parent and patient assessed by questionnaire. • To determine ste</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus cream 1 %</description>
    <other_name>Elidel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 3 months to 12 years old&#xD;
&#xD;
          -  Clinical diagnosis of atopic dermatitis&#xD;
&#xD;
          -  History of mild to moderate atopic dermatitis&#xD;
&#xD;
          -  Investigator Global Assessment ≥ 1 (almost clear/clear of disease)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigator Global Assessment ≥ 4 (severe/very severe disease)&#xD;
&#xD;
          -  Patients with active skin viral infections (i.e, herpes simplex, herpes zoster,&#xD;
             varicella)&#xD;
&#xD;
          -  Patients with atopic dermatitis, with active clinical infection on area of disease.&#xD;
             All active infections must be treated prior to trial inclusion&#xD;
&#xD;
          -  Patients in an Immunosuppressive state or with history of malignant disease&#xD;
&#xD;
          -  Patients with clinical conditions other that Atopic Dermatitis that according to the&#xD;
             investigator may interfere with the evaluation (i.e, Psoriasis, Netherton Syndrome)&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharma AG Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aragua</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site, Edo</name>
      <address>
        <city>Carabobo</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 31, 2007</study_first_submitted>
  <study_first_submitted_qc>July 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2007</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis, pimecrolimus, children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

